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What’s already known about this topic? 
 Some tumours have been shown to emit characteristic patterns of volatile organic 
compounds (VOCs).  
 There is anecdotal evidence of canine olfactory detection of melanoma, and some 
supporting analytical findings, but robust data for a distinct profile of melanoma-
associated VOCs are lacking. 
 
What does this study add? 
 We demonstrated by canine olfaction that invasive melanoma in-vivo emits a profile 
of odorous VOCs which differs from those of basal cell carcinoma, benign naevi and 
healthy skin. 
 The study provides further evidence of the potential for VOCs to be utilised as 
biomarkers for the objective, non-invasive diagnosis of melanoma.   
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Abstract 
 
Background  Volatile organic compounds (VOCs) are continuously released by the body 
during normal metabolic processes, but their profiles change in the presence of cancer, 
offering an objective, non-invasive approach to diagnosis. Robust evidence that invasive 
melanoma in-vivo emits a characteristic VOC signature is currently lacking.  
Objective  To conduct a canine olfactory, proof of principle study, to investigate whether 
VOCs captured from the surface of invasive melanoma are distinguishable from those of 
basal cell carcinoma (BCC), benign naevi and healthy skin in-vivo. 
Methods  After a 13 month training period, the dog’s ability to discriminate melanoma was 
evaluated in a series of 20 double-blind tests, each requiring the selection of one melanoma 
sample from amongst nine controls (three each of BCC, naevi and healthy skin; all samples 
being new to the dog), assuring a power of 88% with respect to the analysis. 
Results  The dog correctly selected the melanoma sample on nine of the 20 occasions, a 
success rate of 45% (exact 95% CI [0.23, 0.68]), compared with the 10% expected by 
chance alone. A one-sided exact binomial test gave a p-value of <0.001, supporting the 
hypothesis that samples were not chosen at random, but that some degree of VOC signal 
from the melanoma samples significantly increased the probability of their detection. Use of 
a discrete choice model confirmed melanoma as the most influential of the recorded 
medical/personal covariates in determining the dog’s choice of sample. Notably, accuracy 
rates based on familiar samples during training were not a reliable indicator of the dog’s 
ability to distinguish melanoma, when confronted with new, unknown samples.  
Conclusions  Our study demonstrates that invasive melanoma in-vivo releases odorous 
VOCs which are distinct from those of BCC, benign naevi and healthy skin, adding to the 
body of evidence that the volatile metabolome of melanoma contains diagnostically useful 
biomarkers.  
 
 
 
Keywords: malignant melanoma; volatile organic compound; canine olfactory detection; 
cancer biomarker; diagnosis 
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Background 
 
Accurate and early detection of malignant melanoma is essential, both to maximise survival 
rates and to reduce the number of pigmented lesions unnecessarily excised.1 However, with 
diagnostic accuracy rates based on visual evaluation running from as low as 22% amongst 
general practitioners, to between 40% and 95% for dermatologists,2-6 there is a need for 
more reliable, objective methods to assist preliminary diagnosis.7,8    
 
A non-invasive diagnostic approach which is currently showing promise for a number of 
disorders, including cancer, is the profiling of volatile organic compounds (VOCs). These 
high vapour pressure compounds are continuously released from the body during normal 
metabolic processes,9,10 but show qualitative and quantitative changes in the presence of 
disease.11-13 Analytical techniques, such as gas chromatography mass spectrometry (GC-
MS), are commonly used in their investigation,9-14 but, since many VOCs are odorous, 
olfactory detection is also possible.15-22      
 
The concept that malignant melanoma may emit a different pattern of VOCs from 
surrounding healthy skin and benign lesions, in fact, originated from canine behaviour linked 
to olfaction. In their anecdotal report published in The Lancet in 1989, Williams and 
Pembroke described the persistent interest shown by a pet dog toward a lesion on its 
owner’s leg, which, on excision, proved to be a melanoma.23  
 
Building on this and other preliminary findings,24 D’Amico et al applied a gas sensor array – 
otherwise known as an electronic nose – to compare the spectrum of VOCs emitted from the 
surface of in-vivo melanomas with those of benign naevi in the same individuals, achieving 
accuracy rates for their identification of 70% and 90%, respectively, albeit with small sample 
sizes.25 Further supporting evidence for a characteristic profile of VOCs for melanoma has 
also come from more recent GC-MS and electronic nose studies of biopsy material and 
cultured cell lines.26-29 
 
Advancing the development of VOC-based diagnostic aids for melanoma, however, calls for 
a greater understanding of the volatile metabolite signatures released directly from the 
surface of a variety of different skin lesions. To that end, we decided to make use of dogs’ 
exquisite olfactory sensitivity, innate pattern recognition skills and proven cancer detection 
ability,16-22 to determine, with greater rigour than previous studies, whether the odour of 
melanoma differs from those of healthy skin and benign naevi, and to examine, for the first 
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time, whether the odour of melanoma differs from that of another skin cancer, namely basal 
cell carcinoma (BCC). It also gave us the opportunity to assess the suitability of a method for 
skin VOC collection, pragmatically chosen as the most clinically practical, in preparation for 
future GC-MS studies.  
 
An experimental design similar to that of our earlier proof of principle for canine olfactory 
detection of bladder cancer16 was employed, the dog, in this case, being required to 
distinguish one melanoma sample from within a line-up of nine controls.  
 
 
Materials and Methods 
 
The study was approved by the National Research Ethics Committee London – Brent (REC 
Ref. 13/LO/1491), and all participants gave written, informed consent. Procedures were 
carried out in accordance with the Declaration of Helsinki of 1975, as revised in 2013. 
 
Participants 
 
In total, 741 study participants were recruited between October 2013 and June 2015. Eligible 
patients were identified from dermatology outpatient clinics, whilst healthy control subjects 
were recruited from amongst staff at Amersham Hospital and their families and friends. 
Overall, 593 patients were recruited from within the Buckinghamshire Healthcare NHS Trust, 
with a further nine patients coming from Oxfordshire University Hospitals NHS Foundation 
Trust. Of the healthy controls, 33 individuals had benign melanocytic naevi, diagnosed 
visually by an experienced dermatologist, but not surgically removed, with the remaining 106 
subjects having normal, healthy skin.  
 
In order to provide a logical progression of samples during training, patients and those 
control subjects with naevi were assigned to one of eight subgroups (Groups 1-8), 
depending on the diagnosis of their skin lesion, whilst volunteers with normal skin were 
categorised into one of four subgroups (Groups 9-12), depending on their age and 
Fitzpatrick skin type30 (Table 1). Details of the characteristics of the subjects within the 12 
groups are given in Table 2. 
   
Demographic details and medical histories (including oral and topical medication history, and 
personal history of diabetes) were obtained from all participants. Lesion details, including 
site, maximum diameter and histological diagnosis, where appropriate, were also recorded. 
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Comprehensive dietary and lifestyle-related metadata were collected to allow for evaluation 
of potential confounding factors. An emphasis was placed on those factors known to affect 
the profile of VOCs released from the skin, including smoking, alcohol consumption, active 
dieting/fasting, anxiety level, strenuous exercise, and ingestion of certain foodstuffs, such as 
garlic and onions.31 Given the ubiquity of perfumed personal and household products, 
subjects were only asked to refrain from the use of perfume itself on the day of sampling. 
 
Exclusion criteria included lesion ulceration, a current or past history (< 5 years) of any non-
dermatological malignancy, mental incapacitation and age < 18 years. Unless specifically 
recruited for the condition, individuals were excluded if they had a current or past history (< 5 
years) of malignant melanoma, melanoma in-situ, lentigo maligna, squamous cell carcinoma 
or Bowen’s disease, or a current history of BCC, actinic keratosis or dysplastic naevi. 
Concurrent benign lesions, such as seborrhoeic keratoses, solar lentigines and benign 
melanocytic naevi, as well as inflammatory conditions, such as hand eczema, were 
permitted, providing they were located a minimum of 20 cm from the lesion of interest. 
 
Skin VOC sampling 
 
Volatile organic compounds were collected from patients, immediately prior to excision or 
biopsy of their lesion, using 100% cotton gauze pads (plain sterile gauze swabs BP [12 ply], 
Synergy Health, Chorley, Lancashire, UK),32,33 cut to size and applied directly to the surface 
of the lesion. Overlaid on top of the gauze to prevent VOC loss into the atmosphere were 
slightly larger pieces of low odour Nalophan® plastic,14 cut from Bacofoil roasting bags 
(Wrap Film Systems Ltd., Telford, Shropshire, UK), which were secured to the skin on all 
sides using 2.5 cm wide Micropore tape (3M Healthcare, Bracknell, Berkshire, UK). 
 
Healthy skin of normal control subjects (matched to patients’ melanoma sites) was sampled 
in an identical manner, using a standard 2 cm2 sized gauze pad. Procedural blanks, 
designed to collect background VOCs, were prepared in parallel with the subjects’ skin 
samples, using gauze pads exposed to the atmosphere for 10 min, and then sandwiched 
between two layers of Nalophan® and sealed with Micropore tape for a further 10 min. 
 
Gauze pads were left in contact with the skin for 15 min, after which time they (and the 
procedural blanks) were placed immediately in 7 mL, screw neck, amber glass vials 
(SCHOTT; Adelphi Healthcare Packaging, Haywards Heath, West Sussex, UK), closed with 
18 mm black urea caps with foil liners (Wheaton UK Ltd., Rochdale, UK), frozen and stored 
at -40 oC until required. 
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Over 92% of subjects (and 100% of those used in the final testing phase) were sampled in a 
dedicated clinical research room (Amersham Hospital), at a temperature maintained at 22 oC 
+/- 1 oC. At other hospital sites, the temperature ranged from 20 oC to 24 oC. Powder-free 
vinyl gloves were worn by researchers and dog trainers throughout. 
 
Training of the dog 
 
Two dogs began training in January 2014, but, due to the time commitment required, the 
owner/trainer of one of them (LK) withdrew from the study later that year. Only one dog, a 
working Labrador (Ronnie, male, 2 years old at the start of the study; Fig. 1), which was 
obedience trained, but had no prior training in scent discrimination, therefore completed the 
study. His owner/trainer (MAS) has over 40 years’ experience of selecting and training dogs 
for scent discrimination tasks on behalf of such organisations as the police and customs and 
excise, and has also been involved in a number of university-led research projects in the 
fields of forensics and wildlife conservation.  
 
Training was conducted over a 13 month period, the ultimate goal being that the dog should 
be able to distinguish one melanoma odour sample from within a line-up containing nine 
non-melanoma controls (all samples being entirely new to the dog) with a success rate, after 
20 test sets, greater than would be expected by chance alone.  
 
Operant conditioning to attain the desired alert of ‘freezing’ in front of the positive melanoma 
sample was achieved by positive reinforcement, using ball play as the reward, in conjunction 
with the clicker. Early recognition of the melanoma scent was facilitated by search and find 
games using samples from several different patients. These were gradually replaced over a 
period of a few weeks by a more structured discriminatory search for the melanoma from 
amongst controls, along a line of, first two, and then up to ten, samples. The gauze-
containing vials, which remained stored at -40 oC at the training facility when not in use, 
were placed in 2.5 cm diameter holes drilled 40 cm apart along wooden planks to a depth 
sufficient to prevent the dog dislodging them. The vial necks were too narrow to allow the 
dog to make direct contact with the samples. Prior to training (and testing), the samples were 
allowed to warm up to ambient temperature. To preserve the odour as much as possible (as 
samples were used on multiple occasions), the vial tops were removed immediately before 
the dog entered, and replaced as soon as the search was complete.  
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Control samples, against which successive melanoma samples were run, were introduced in 
a step-wise fashion of increasing pathological significance (i.e. descending order of the 
sample groups given in Table 1), beginning with procedural blanks, and gradually 
progressing to normal skin controls and then to the various non-melanoma lesion types. 
Initially, we did not restrict the range of non-melanoma control lesions used in training; 
however, as explained below, this later became necessary.  
 
At no time was there more than one melanoma sample in a run; however, in order to 
minimize expectation bias, the trainer’s assistant included random, blinded, no-melanoma 
runs (i.e. all negative controls) during each training session. Training took place four times a 
week, each session lasting about 30 minutes, with the dog being worked, off-lead, on three 
or four runs of different combinations of samples. 
 
Preliminary assessment of the dog  
 
Six months into training, the dog had been exposed to the odours from 17 invasive 
melanomas and almost 200 control odours, taken from over 50 different types of non-
melanoma skin lesion. At this stage, MAS reported back a near 100% success rate in 
identifying the melanomas, and so it was decided to begin a series of double-blind tests 
(methodology as described below, all samples being new to the dog, with the nine controls 
being selected from Groups 3 to 12). However, after 13 runs, the dog had successfully 
identified only one of the melanoma samples, with no particular pattern to the chosen control 
samples, suggesting that the dog had been merely scent-matching known samples, and had 
failed to learn a generic odour for melanoma. 
 
We speculated that the use of so many diverse control lesions might have been hampering 
the dog’s ability to find the ‘common denominator’ between melanoma samples, and so took 
the decision to simplify the task, restricting the types of control samples to just three 
categories: BCC (Group 4), benign naevi (Group 6) and normal skin (Groups 9 to 12). 
Training with all other samples (i.e. those in Groups 2,3,5,7 and 8) was stopped, and fresh 
melanoma and appropriate control samples were collected and passed to MAS to further 
train the dog.  
 
Final testing of the trained dog 
 
In early 2015, the dog had been trained on a total of 41 melanoma samples, 114 BCCs, 51 
benign naevi and 46 normal skin samples, and the results of mock tests were more 
encouraging. Testing was recommenced between February and June 2015, and 20 
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consecutive double-blind tests were carried out using new samples throughout. No duplicate 
sample was used within or between test sets, and all samples came from different 
individuals. All lesions had histological diagnoses. 
 
Each test set consisted of one melanoma, three BCCs, three benign naevi and three normal 
skin samples. Careful consideration was given to the combination of controls to ensure that 
key characteristics of the melanoma samples were adequately matched (Table 3; 
Supplementary File 1). Where gender-specific panels were not possible (due to the on-going 
nature of sample collection), at least two controls with the same gender as the melanoma 
patient were used. Two or more controls were of equivalent age or older than the melanoma 
subject, and at least three controls were matched with respect to the site of the lesion and 
the size of area sampled. Matching with two or more controls was also carried out for 
Fitzpatrick skin type, diabetes status, smoking, alcohol and garlic consumption. 
 
Sample vials were numerically coded from 0 to 9 at Amersham Hospital, using the random 
number generator in Excel, and were then sent by express delivery to the training centre, 
where they were immediately refrozen. For each test, the assistant at the training centre 
(who was not part of the hospital team) laid out the thawed samples in numerical order 
(although the positions could be changed, if requested by MAS, to confirm the dog’s alert to 
a particular vial, or to check for possible positional bias). As soon as MAS was satisfied with 
the dog’s alert, he named the putative positive sample, and CW, in telephone contact (from 
Amersham Hospital) with the assistant during the test, broke the sample codes. This allowed 
the dog to be immediately rewarded if correct, and for MAS to further train the dog on the 
line if incorrect. All samples were then added to the training pool. On the two occasions 
when the dog failed to make a clear alert, the codes remained unbroken, and the tests were 
re-run on another day. One new test was conducted per week, with training sessions in 
between. 
 
Statistical analysis 
 
Power and sample size determination 
Following consultation with the trainer, it was decided that ten samples per test set (one 
melanoma plus nine controls) was the maximum that a dog could realistically be expected to 
manage in a single line-up. The primary outcome measure was thus the proportion of 
successes for the dog, compared with an expected value of 1 in 10 (0.1).  
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The package, nQuery Advisor 6.02 (Statistical Solutions Ltd., Cork, Ireland), was used to 
assess the powers for various sample size combinations, assuming a significance level of 
5% for all calculations. Since in our original bladder cancer study, the dogs were correct 41% 
(0.41) of the time,15 we calculated the powers associated with predicted rates of success of 
0.35, 0.4 and 0.5, which, for 20 separate tests, were 88%, 94% and >99%, respectively. 
Therefore, 20 test sets, each consisting of one melanoma sample, and nine non-melanoma 
samples, were deemed to provide sufficient power.   
 
Exact binomial test 
Following the completion of the double-blind tests, the exact binomial test was used to 
examine the hypothesis that the samples were chosen at random in each test set (with the 
hypothesised probability of choosing the melanoma sample being 0.1). The one-sided test 
was deemed most suitable here as interest is in whether the melanoma samples were 
chosen more often than would be expected under the assumption of choosing samples at 
random. However, for completeness, a two-sided test was also included. 
 
Model of sample choice 
A discrete choice model (conditional logit) was used to explore the covariates most 
influential in determining the dog’s choice of sample from each test set. The outcome was 
the sample chosen, with the characteristics of the sample (either melanoma, BCC, benign 
naevus or normal skin, with no further subtype classification), together with medical/personal 
information on the participants, used as potential covariates. The latter were first screened to 
assess their suitability for inclusion; binary covariates for which there was little variability 
between participants, or which were only weakly associated with the chosen samples, were 
excluded.  
 
Seventeen covariates, in addition to lesion diagnosis, remained after this screening 
(Supplementary File 2), so a backward stepwise approach was used to choose an initial 
model.34 Covariates with a p-value greater than 0.2 were sequentially deleted, followed by 
further elimination of the remaining covariates based on likelihood ratio tests.35  
 
As the effective sample size was small, we applied Estrella’s goodness-of-fit measure,36 
which penalises for both small sample size and the number of estimated parameters, to 
assess the fit of the final model to the data. There is evidence, however, that a sample size 
of 20 may be sufficient under the assumption that each test panel of ten skin samples is 
equivalent.37  
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Results 
 
Table 4 gives a summary of the samples chosen by the dog during the 20 double-blind test 
runs (see also Supplementary File 1 for metadata on the 200 subjects), with Table 5 
summarizing the tumour characteristics of the melanoma samples.  
 
With 20 test sets, each containing ten samples, and only one classified as melanoma in 
each set, the dog would be expected to correctly identify the melanoma samples by chance 
alone on four occasions at most (one-sided binomial test for four successes in 20 tests gives 
a p-value of 0.13). However, the dog correctly selected the melanoma sample in nine of the 
20 tests (proportion correctly identified was 0.45, with exact 95% CI [0.23, 0.68]). The one-
sided exact binomial test gave a p-value of less than 0.001, supporting the hypothesis that 
samples were not chosen at random from each test set, but that some degree of VOC signal 
from the melanoma samples significantly increased the probability of their detection. The 
equivalent two-sided test resulted in a p-value which was also less than 0.001. 
 
In the 11 tests where an alternative sample category to melanoma was chosen, six were 
BCC samples, and five were benign naevi. Since no normal healthy skin samples were 
chosen from any test set, the exact binomial test was further used to investigate whether 
samples were chosen at random from within the seven non-normal skin samples. Again, 
both one- and two-sided tests yielded p-values of less than 0.001, and even after applying 
the very conservative Bonferroni correction for multiple testing,38 all p-values were still 
significant at the 0.01 level. 
 
The discrete choice model pointed to a number of covariates which were seemingly 
associated with a sample being chosen (Table 6); nonetheless, melanoma remained the 
most significant predictor in sample choice, based on the p-value obtained for each variable 
in the model. Hence, the above result using an exact binomial test, where covariates were 
not considered, was not contradicted. Applying Estrella’s goodness-of-fit measure gave a 
value of 0.73 (where a value of 0 indicates no fit, and 1 indicates perfect fit), providing 
evidence in favour of our model.   
 
Although of clinical interest, there were insufficient data to examine the relationship between 
dog’s sample choice and tumour characteristics of the melanoma (Breslow thickness etc.). 
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Nor was it considered appropriate to estimate the sensitivity and specificity of the dog, since 
this experimental design (where the dog alerts to one sample out of ten) precludes the 
independent assessment (i.e. a 50-50 chance of being correct) of each sample. 
 
 
Discussion 
 
In this study, we have shown that a dog can be trained to distinguish patients with invasive 
melanoma from those with BCC, benign naevi and healthy skin, on the basis of skin surface 
odour, with significantly greater accuracy than would be expected by chance alone. From 
this, we can infer that melanoma releases a profile of VOCs from its surface which is 
different from those of the three control groups included in the study – in the case of BCC, 
the first time, to our knowledge, that this has been reported for lesions in-vivo. The findings 
therefore add weight to a novel VOC-based diagnostic approach to melanoma, whilst at the 
same time validating our method for skin VOC collection, but, importantly, do not at this 
stage demonstrate clinical usefulness.  
 
Our experimental design, in which the dog was remote from the subjects at all times, 
necessitated the capture and subsequent storage of the VOCs emitted from the skin. 
Although initially we considered using an absorptive fibre-filled funnel upturned over the area 
of interest, in a similar set-up to that designed by Gallagher et al,9 it became apparent that 
too many of the lesions were located on uneven, awkward body sites for this to be 
successful. For this reason, we focused on direct contact sampling patches. These have the 
advantage of conforming to the anatomical contours of the body, can be cut to the 
appropriate size of the lesion, are low-cost and easy to handle.  
 
With regard to the choice of material comprising the patches, this has been the subject of a 
number of studies pertaining to canine scenting in forensic science,32,33 and the optimum 
fibre, in terms of the greatest variety and quantity of skin surface VOCs collected and readily 
released, appeared at the outset of this study to be 100% cotton; we therefore employed a 
widely available, sterile, pure cotton gauze throughout. As for the chosen sampling time of 
15 mins, we were again guided by the forensic science literature.32 Multiple use of the same 
sample during training did not appear to lead to a significant loss of volatile signature, since 
the dog continued to successfully select known melanoma samples used up to 15 times over 
a period of 18 months post-collection.  
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Although the original aim was to train and test the dog against the widest possible range of 
control lesions, the dog failed to learn a generic odour for melanoma after six months, 
prompting the decision to limit the breadth of controls. Importantly, this lack of success had 
not been the impression of the trainer on the strength of his results using a large battery of 
samples on a repeated basis; only through double-blind testing using new samples did it 
become apparent. Our experience closely mirrors that of Elliker et al when attempting to 
train dogs to detect prostate cancer,39 and serves to highlight the danger of citing canine 
accuracy rates based on training samples. 
 
The need to reduce the diversity of control odours presented to the dog is perhaps not 
surprising, since, for over half of the lesion types, only one or two representatives were 
available during training. The challenge was compounded by the wide variation in lesion site, 
which is known to give rise to significant qualitative differences in VOC emission.9 
Furthermore, there is a high likelihood of overlapping VOC profiles amongst melanocytic 
lesions displaying the full spectrum of cellular abnormality, from mild dysplasia through in-
situ disease to invasive malignancy. A more generous and continuous supply of known 
positives and negatives during training may have overcome this, since the most successful 
period during the double-blind tests coincided with the simultaneous introduction of a large 
number of supplementary training samples, but, unfortunately, resources and the availability 
of suitable patients were limited. 
 
Resources permitting, we would also have employed additional dogs to possibly increase 
the chances of a higher level of discrimination. We acknowledge that using only one dog 
was a study limitation; however, we had confidence in the ability of our trainer to select a dog 
with the necessary attributes.40 Failing to achieve the high accuracies reported by others for 
different types of cancer18,21,22 may therefore be a reflection of the difficulty of this particular 
task, rather than deficiencies on the part of the dog. 
 
Restricting the scope of the controls had the indirect advantage, however, of providing a 
greater robustness to the statistical analysis, particularly in view of the many potential 
confounding factors, in addition to site, within the melanoma and control groups. When 
recruiting the subjects, we collected detailed and comprehensive medical and personal 
information, with around 50 variables recorded. Common to such high-dimensional 
datasets,41 several covariates of statistical significance emerged in the discrete choice 
model, two of which, room temperature and skin type, are of dubious relevance to the data. 
The former fluctuated to such a minor degree (+/- 1 oC) that it is unlikely to have influenced 
the temperature of the occluded skin during sampling, whilst the latter would have become a 
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concern only if the dog had selected patients at either end of the Fitzpatrick scale; a bias 
towards subjects with skin types IV-VI, for example, may have been an indication that the 
dog was generalising on the odour of melanin itself, but this was clearly not the case. 
Alcohol consumption within the previous 24 hours does warrant consideration, however, but 
is unlikely to be a factor in the dog’s choice of sample. None of the participants admitted to 
consuming alcohol on the actual day of sampling/surgery, and so the probability of 
significant amounts of alcohol remaining in their bloodstreams is low.  
 
Although our findings lend support to the concept of a distinctive VOC signature for 
melanoma, our aim in conducting this study was not to potentially add weight to the notion 
that dogs can be used in actual clinical diagnosis. High sensitivities and specificities for 
some cancers have been reported in several research studies,18,21,22 but the suitability of 
dogs for high-volume screening of unknown samples has yet to be determined.42 Introducing 
canine diagnosis of cancer in the absence of adequate validation, and without external 
quality control assurance mechanisms in place, may raise some of the same patient safety 
issues as those highlighted by the British Medical Association in their 2005 report on 
unregulated screening tests, more generally.43 However, within the context of research, we 
believe that utilising the exquisite olfactory sensitivity and innate pattern recognition skills of 
dogs represents a logical and potentially valuable step in the search for volatile biomarkers 
of cancer.   
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Table 1. Categorisation of the different skin lesion types and normal skin samples to provide 
a logical progression of samples for dog training (N=741).  
 
Diagnosis (no. of subjects) Group 
No. of 
subjects 
Melanoma (T1-T4, Clark level > 2) (superficial spreading [52], lentigo 
maligna melanoma [5], nodular [3], Spitzoid [1]) 
1 61 
Melanoma in-situ (Tis, Clark level 1)  2 27 
Squamous cell carcinoma 3 22 
Basal cell carcinoma (subtypes: nodular [65], nodular and superficial 
[27], nodular and infiltrative [23], superficial [24], infiltrative [10], 
nodular, superficial and infiltrative [5], nodulocystic [5], pigmented 
superficial [5], pigmented nodular [4], nodulocystic and superficial [2], 
pigmented, nodular and superficial [2], nodulocystic and infiltrative [1], 
pigmented, nodular, superficial and infiltrative [1]) 
4 174 
Dysplastic lesions (dysplastic naevus [63], pigmented actinic keratosis 
[3], actinic keratosis [38], Bowen's disease [6]) 
5 110 
Benign naevus (benign melanocytic naevus [61], intradermal naevus 
[16], compound naevus [11], blue naevus [10], Spitz naevus [8], acral 
naevus [2], lentiginous naevus [1], benign junctional naevus [1], 
Meyerson’s naevus [1]) 
6 111 
Benign non-naevus (solar lentigo [12], pigmented seborrhoeic 
keratosis [4], late stage lichenoid keratosis [3], large cell acanthoma 
[2] seborrhoeic keratosis [40], cellular dermatofibroma [9], 
haemangioma [8],keratoacanthoma [7], early stage lichenoid keratosis 
[5], eccrine poroma [2], hidrocystoma [2], pyogenic granuloma [2], 
trichoepithelioma [1], clear cell acanthoma [1], fibroepithelial polyp [1], 
papilloma [1], hydradenoma [1]) 
7 101 
Inflammatory and miscellaneous (inflammatory changes [8], post-
inflammatory pigmentation [3], scarring [3], sebaceous hyperplasia [3], 
lichen planus [3], trauma [1], , mucous cyst [1], fibrous papule [1], 
varicose eczema [1], venostasis [1], arteriovenous malformation [1], 
follicular keratosis [1], folliculitis [1], foreign body reaction [1]) 
8 29 
Healthy skin from subjects ≥ 31 y, skin types IV – VI 9 5 
Healthy skin from subjects ≥ 31 y, skin types I – III 10 73 
Healthy skin from subjects ≤ 30 y, skin types IV – VI 11 11 
Healthy skin from subjects ≤ 30 y, skin types I – III 12 17 
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Table 2. Baseline characteristics of the subjects within each group (training and test samples 
combined; N = 741) 
 
Group No. of 
subjects 
No. of  
males 
No. of 
females 
Age range 
(y) 
Median age 
(y) 
1 61 34 27 24 - 87 65 
2 27 15 12 38 - 82 72 
3 22 17 5 65 - 90 76 
4 174 100 74 36 - 87 70 
5 110 58 52 20 - 88 67 
6 111 35 76 18 - 72 35 
7 101 50 51 21 - 88 65 
8 29 10 19 30 - 86 66 
9 5 1 4 41 - 57 52 
10 73 14 59 31 - 76 57 
11 11 4 7 18 - 28 24 
12 17 3 14 20 - 30 27 
(Group 1 = invasive melanoma; 2 = melanoma in-situ; 3 = squamous cell carcinoma; 4 = basal cell 
carcinoma; 5 = dysplastic lesions; 6 = benign naevi; 7 = benign non-naevus lesions; 8 = inflammatory 
and miscellaneous lesions; 9-12 = normal healthy controls of varying skin types and ages) 
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Table 3. Baseline characteristics of the participants/samples selected for the 20 double-blind tests, showing age, gender, body site (Abd = 
abdomen) and max. diameter (mm). Full medical and lifestyle details are given in Supplementary File 1.  
 
Sample 
type 
Test Sets  
1 2 3 4 5 6 7 8 9 10 
Melanoma 74F, Leg, 12 42F, Arm, 12  46F, Arm, 9  50M, Leg, 20  61M, Back, 15  75M, Back, 18 77F, Arm, 10  41F, Leg, 8  66M, Abd, 20  65M, Back, 10  
BCC 
 
79F, Leg, 12 79F, Arm, 10  69F, Arm, 9  77M, Face, 20  73M, Chest, 7  84M, Face, 8  78F, Face, 11  73M, Scalp, 6  75M, Face, 9  83M, Face, 7  
73F, Face, 5  5 F, Arm, 9 67F, Face, 4  69M, Leg, 6 59M, Back, 6  76M, Face, 6  65F, Arm, 10,  63M Face, 6  60M, Face, 20  70M, Leg, 7  
65F, Leg, 12  47F, Leg, 7  67F, Chest, 7  66M, Face, 3  44M, Abd, 11 74M, Back, 18  62M, Arm, 8,  50M, Leg, 3  60M, Face, 6  69M, Face, 12  
Benign 
Naevus 
74F, Face, 5, 35F, Back, 15  48F, Abd, 6  55M, Abd, 15  63M, Arm, 8  49F, Abd, 6  78F, Arm, 4,  43F, Leg, 6  45M, Back, 6  46M, Back, 5  
56F, Arm, 4, 31F, Arm, 6  40F, Arm, 3  25M, Back, 5  54M, Back, 6  44M, Back, 6  49F, Back, 6  31F, Abd, 4  40F, Arm, 5  36F, Back, 6  
18F, Foot, 12  21F, Leg, 4  22F, Back, 4  21M, Back, 3  37M Back, 6 33F, Neck, 7  35F, Back, 7  18F, Arm, 9  32F, Abd, 7  30M, Arm, 6  
Normal 
Skin 
72F, Leg, 20 41F, Arm, 20  59F, Arm, 20  38M, Leg, 20  60F, Back, 20  70F, Back, 20  76F, Arm, 20  41F, Leg, 20  67F, Abd, 20  71F, Back, 20  
30F, Leg, 20 40F, Arm, 20  57F, Arm, 20  34M, Leg, 20  48M, Back, 20  68F, Back, 20 57F, Arm, 20  32F, Leg, 20  60F, Abd, 20  51F, Back, 20  
20F, Leg, 20 27F, Arm, 20  42F, Arm, 20  30M, Leg, 20  45F, Back, 20  20M, Back, 20  50M, Arm, 20  28F, Leg, 20  50F, Abd, 20  39F, Back, 20  
 
Sample 
type 
 
Test Sets 
11 12 13 14 15 16 17 18 19 20 
Melanoma 75F, Leg, 7  71M, Chest, 12  79M, Leg, 4  70F, Leg, 15  75M, Back, 10  80M, Chest, 10  83M, Abd, 18  45M, Arm, 10  51M, Back, 15  76F, Leg, 12  
BCC 
 
77F, Face, 8  73M, Arm, 7  80M, Chest, 12  85F, Face, 7  78M, Face, 10  82F, Face, 11  84F, Hand, 6  77M, Back, 10  71M, Leg, 15  78M, Face, 15  
68F, Neck, 6  63M, Abd, 12  82F, Leg, 12  77M, Back, 9  76F, Neck, 8  81M, Face, 5  85F, Face, 20  66M, Face, 10  67M, Chest, 13  77M, Chest, 10  
48F, Leg, 4  52F, Chest, 10  51M, Face, 5  68M, Scalp, 18  67F, Back, 8  79F, Arm, 20 80F, Face, 6 60M, Back, 20  55M, Face, 10  72F, Face, 6  
Benign 
Naevus 
36F, Arm, 5  74M, Back, 5  49F, Face, 5  49F, Face, 5  35F, Neck, 9  49F, Back, 4  62F, Face, 5  44M, Back, 5  56M, Back, 6  49F, Face, 5  
32F, Neck, 6  32F, Abd, 6  33F, Abd, 5  29F, Abd, 9  34F, Back, 7  34F, Face, 6  34F, Ear, 6 40M, Back, 4  32F, Back, 7  41F, Leg, 8  
20F, Leg, 4 28M, Arm, 6  29M, Arm, 6  26F, Leg, 9 27F, Chest, 7  23F, Neck, 4  22F, Neck, 7  26M, Back, 6  22F, Leg, 4  34F, Leg, 6  
Normal 
Skin 
78F, Leg, 20 56F, Chest, 20  51F, Leg, 20  71F, Leg, 20  65M, Back, 20  66M, Chest, 20 71M, Abd, 20  38M, Arm, 20  40F, Back, 20  73F, Leg, 20  
56F, Leg, 20  51F, Chest, 20  24F, Leg, 20  48F, Leg, 20  50F, Back, 20  26F, Chest, 20  68M, Abd, 20 28M, Arm, 20  25F, Back, 20  49F, Leg, 20  
55F, Leg, 20  44F, Chest, 20  24F, Leg, 20  32F, Leg, 20 24F, Back, 20  24F, Chest, 20  28F, Abd, 20 27M, Arm, 20  23M, Back, 20  30F, Leg, 20  
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Table 4. Summary of the baseline characteristics of the samples selected by the dog handler 
on the basis of the dog’s alert in the 20 double-blind tests (further metadata given in 
Supplementary File 1).  
 
Test 
Set 
No. 
Lesion (sample no.) 
Age 
(y) 
Sex 
Skin 
type   
(I-VI) 
Site 
Max. 
diam. 
(mm) 
1 Intradermal melanocytic naevus (1/4) 74 F I Face 5 
2 Malignant melanoma (2/0)  42 F II Arm 12 
3 Malignant melanoma (3/0) 46 F II Arm 9 
4 Basal cell carcinoma (4/2) 69 M III Leg 6 
5 Common blue naevus (5/4) 63 M III Arm 8 
6 Malignant melanoma (6/0) 75 M III Back 18 
7 Common blue naevus (7/4) 78 F I Arm 4 
8 Basal cell carcinoma (8/2) 63 M I Face 6 
9 Basal cell carcinoma (9/1) 75 M III Face 9 
10 Malignant melanoma (10/0) 65 M III Back 10 
11 Malignant melanoma (11/0) 75 F III Leg 7 
12 Malignant melanoma (12/0) 71 M II Chest 12 
13 Malignant melanoma (13/0) 79 M III Leg 4 
14 Malignant melanoma (14/0) 70 F III Leg 15 
15 Basal cell carcinoma (15/1) 78 M III Face 10 
16 Basal cell carcinoma (16/3) 79 F II Arm 20 
17 Compound melanocytic naevus (17/6) 22 F III Neck 7 
18 Basal cell carcinoma (18/2) 66 M II Face 10 
19 Malignant melanoma (19/0) 51 M II Back 15 
20 Benign intradermal naevus (20/6) 34 F II Leg 6 
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Table 5. Characteristics of the malignant melanomas (all superficial spreading) used in the 
double-blind tests (further metadata given in Supplementary File 1). 
 
Test 
Set 
No. 
Correctly 
chosen 
by dog 
handler 
(X) 
 
Tumour site 
 
Breslow 
thickness 
(mm) 
 
Clark 
level 
 
Micro-
stage 
 
Max. 
diam. 
(mm) 
1  Leg – left, anterior lower 0.8 4 pT1a 12 
2 X Arm – left posterior upper 1.5 4 pT2a 12 
3 X Arm – right posterior upper 0.8 4 pT1b 9 
4  Leg – left anterior upper 1.8 4 pT2a 20 
5  Back – right scapula 3.7 4 pT3a 15 
6 X Back – right scapula 1.4 3 pT2a 18 
7  Arm – left posterior forearm 6.0 4 pT4a 10 
8  Leg – right anterior upper 0.4 2 pT1a 8 
9  Abdomen – left lower 0.4 3 pT1a 20 
10 X Back – left lower 1.2 4 pT2a 10 
11 X Leg – right anterior lower 0.5 2 pT1a 7 
12 X Chest – right upper 0.3 3 pT1a 12 
13 X Leg – left posterior upper 0.2 2 pT1a 4 
14 X Leg – left posterior lower 5.0 4 pT4b 15 
15  Back – right upper 3.9 4 pT3b 10 
16  Chest – right anterior 0.5 3 pT1b 10 
17  Abdomen – left flank 1.1 3 pT2a 18 
18  Arm – right anterior forearm 0.9 4 pT1b 10 
19 X Back – left upper 1.2 3 pT2a 15 
20  Leg – left anterior upper 0.3 2 pT1a 12 
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Table 6. Covariates which remain in the discrete choice model. The outcome of interest is 
the sample chosen, and the covariates were all suitable characteristics of each of the 
samples and their donors.  
 
Variable Regression 
coefficient 
p-value Comments 
Melanoma 
(yes/no) 
1.71 0.002 Increased probability of choosing 
melanoma over other sample types 
Skin type III  
(yes/no) 
1.44 0.024 Increased probability of choosing those who 
had skin type III over other skin types. 
Alcohol 1.40 0.025 Increased probability of choosing those who 
had consumed alcohol in the previous 24h 
Sampling 
temperature 
-0.73 0.057 Probability of being chosen decreases as 
sampling temperature increases.  
Age 0.03 0.102 Probability of being chosen increases with 
increased age (not statistically significant)  
 
 
 
